Small RNAs (sRNAs) are important regulatory molecules, and there are three main sRNA lessons in plants: microRNAs (miRNAs), phased small interfering RNAs (phased siRNAs or phasiRNAs), and heterochromatic siRNAs (hc-siRNAs). Excluding miRNAs, the opposite two lessons should not properly annotated or out there in public databases for many sequenced plant genomes. We carried out a complete sRNA annotation of 143 plant species which have absolutely sequenced genomes and next-generation sequencing sRNA knowledge publicly out there.
The outcomes can be found by way of an internet repository known as sRNAanno ( www.plantsRNAs.org ). Compared with different public plant sRNA databases, we obtained was rather more miRNA annotations, that are extra full and dependable as a result of of the constant and extremely stringent standards used in our miRNA annotations. sRNAanno additionally supplies free entry to genomic data for >22,721 PHAS loci and >22 million hc-siRNA loci annotated from these 143 plant species. Both miRNA and PHAS loci may be simply browsed to view their foremost options, and a group of archetypal trans-acting siRNA 3 (TAS3) genes had been annotated individually for fast entry.
To facilitate the benefit of sRNA annotation, sRNAanno supplies free service for sRNA annotations to the group. In abstract, the sRNAanno database is a superb useful resource to facilitate genomic and genetic analysis on plant small RNAs.Decompression illness (DCS) stays a significant operational concern for diving operations, submarine escape and high-altitude jumps. Aside from DCS signs, venous fuel emboli (VGE) detected with ultrasound post-dive are sometimes used as a marker of decompression stress in people, with a specificity of 100% regardless that the sensitivity is poor [1]. Being non-invasive, moveable and non-ionizing, ultrasound is especially suited to common and repeated monitoring. It might assist elucidate inter- and intra-subject variability in VGE and DCS susceptibility, however analyzing these recordings stays a cumbersome process [2].
Testing repository security evaluation fashions for deep geological disposal utilizing legacy contaminated websites
An necessary property of areas chosen to host deep geological repositories for increased stage radioactive wastes is their capability to retard the motion of any radionuclides launched from engineered limitations. Site characterization can’t measure this attribute immediately and therefore fashions kind the important hyperlink between subject observations and supporting laboratory rock/water/radionuclide interplay research. However, residual uncertainties all the time stay, related to the complexity of radionuclide interactions in pure environments and the extrapolations in time and area which can be included in security assessments. An under-used useful resource that might assist to strengthen the security instances that make the most of such data, is the data base out there from anthropogenically contaminated websites.
These have the potential to mix related geological settings with the radionuclides of curiosity and timescales in the order of many years enable usually gradual processes to be higher quantified. This paper supplies an summary of the vary of choices out there, critically critiques some related examples the place radionuclide migration fashions might be examined and descriptions work that might facilitate utilization of this potential useful resource in order to strengthen the security case for geological repositories.
Repository corticotropin injection (RCI), a posh combination of adrenocorticotropic hormone (ACTH) analogs and different pituitary peptides, has been discovered to suppress key points of gene expression and mobile operate in human B lymphocytes in vitro. The current research reveal that neither particular person POMC peptides nor different associated pituitary neuropeptides are ample to elicit these results, regardless that particular receptors succesful of transmitting indicators from these peptides are expressed by human B cells. RCI’s direct results on human B cells could require complementary indicators from a number of elements of the preparation.
Medicine Shortages: From Assumption to Evidence to Action – A Proposal for Using the FMD Data Repositories for Shortages Monitoring
Medicine shortages could negatively affect affected person care and the affected person expertise. Shortages needs to be a precedence of trade, provide chain stakeholders and nationwide competent authorities, and deserve greater than empathy or “lip-service” however critical engagement and motion. Under the overarching precept that with out right measurements in place there can’t be any enchancment in general efficiency (1), stakeholders in the pharmaceutical provide chain, notably pharmaceutical producers have made the decision for all related sources of data for use in order to offer further intelligence concerning the root causes and drivers of shortages, together with the identification of bottlenecks in the availability chain.
This paper outlines a proposal for utilizing the info saved in the interoperable community of nationwide repositories being arrange in the context of the Falsified Medicines Directive (Directive 2011/62/EU) and its Delegated Regulation 2016/161/EU on security options for offering further intelligence in monitoring shortages. The paper analyses the potential feasibility and readiness of utilizing this knowledge for monitoring shortages in addition to the strengths and weaknesses of the strategy. We discover additionally what are some of the opposite complementary knowledge sources that might be analyzed in conjunction with the info in the repository system to sharpen the general evaluation.
 Anti-Tetanus Toxoid scFv IgG) Recombinant (E.Coli) Anti-Tetanus Toxoid scFv IgG |
|
RP-343 |
Alpha Diagnostics |
10 ug |
EUR 286 |
 scFv-Fc-Sec ADC) Anti-ROR1 (clone R11) scFv-Fc-Sec ADC |
|
ADC-W-434 |
Creative Biolabs |
1mg |
Ask for price |
|
Description: This ADC product is comprised of an anti-ROR1 scFv-Fc (clone R11) conjugated via a engineered selenocysteine (Sec) residue linker to a drug |
) Control siRNA Vector (pGB-control) |
|
9500C-20 |
Biovision |
|
EUR 338 |
) Recombinant Anti-CTLA4 x Anti-PD1 Bispecific Antibody (IgG-scFv) |
|
IGFV-146 |
Creative Biolabs |
200μg |
Ask for price |
|
Description: A bispecific antibody that is expressed as a LC and an extended HC with scFv moiety linked to the C terminus. It is a symmetric bispecific and tetravalent molecule, 2+2 antigen-binding valency. This BsAb can bind two factors simultaneously and enhance immune response. It is designed for the research of Tumors therapy. |
) Recombinant Anti-IL17 x Anti-TNF Bispecific Antibody (IgG-scFv) |
|
IGFV-175 |
Creative Biolabs |
200μg |
Ask for price |
|
Description: A bispecific antibody that is designed to be expressed as a LC and an extended HC with scFv moiety linked to the C terminus. It is a symmetric bispecific and tetravalent molecule, 2+2 antigen-binding valency. This BsAb can block two proinflammatory cytokines simultaneously. It is designed for the research of Rheumatoid arthritis (RA); Plaque psoriasis therapy. |
) Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-020-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy. |
Recombinant Anti-BCMA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-020-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-BCMA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Multiple myeloma (MM) therapy. |
) Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-030-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-030-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD123 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
) Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-041-100ug |
Creative Biolabs |
100μg |
EUR 3794 |
|
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy. |
Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-041-50ug |
Creative Biolabs |
50μg |
EUR 2156 |
|
Description: A bispecific antibody that is expressed as an anti-CD19 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy. |
) Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv) |
|
BSFV-046-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-CD2 x Anti-EGFR Bispecific Antibody (Tandem scFv) |
|
BSFV-046-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD2 scFv fused with an anti-EGFR scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells and is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
) Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-066-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy. |
Recombinant Anti-CD33 x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-066-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD33 scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myeloid leukemia (AML); Ulcerative Colitis (UC); Myelodysplastic syndromes (MDS); Gastric cancer therapy. |
) Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv) |
|
BSFV-072-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy. |
Recombinant Anti-CD3 x Anti-CEA Bispecific Antibody (Tandem scFv) |
|
BSFV-072-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-CEA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Colorectal cancer (CRC); Breast cancer; Lung cancer; Gastric cancer therapy. |
) Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-077-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
Recombinant Anti-EGFR x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-077-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-EGFR scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy. |
) Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-079-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy. |
Recombinant Anti-EPCAM x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-079-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-EPCAM scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Solid tumors therapy. |
) Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv) |
|
BSFV-102-100ug |
Creative Biolabs |
100μg |
EUR 3560 |
|
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy. |
Recombinant Anti-CD3 x Anti-PSMA Bispecific Antibody (Tandem scFv) |
|
BSFV-102-50ug |
Creative Biolabs |
50μg |
EUR 2039 |
|
Description: A bispecific antibody that is expressed as an anti-CD3 scFv fused with an anti-PSMA scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can retarget T cells to tumor cells. It is designed for the research of Prostate cancer therapy. |
) Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv) |
|
BSFV-162-100ug |
Creative Biolabs |
100μg |
EUR 3794 |
|
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy. |
Recombinant Anti-FIXa x Anti-FX Bispecific Antibody (Tandem scFv) |
|
BSFV-162-50ug |
Creative Biolabs |
50μg |
EUR 2156 |
|
Description: A bispecific antibody that is expressed as an anti-FIXa scFv fused with an anti-FX scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can bind and dimerize two factors. It acts as mimetic FXIII. It is designed for the research of Hemophilia A therapy. |
) Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-c001-100ug |
Creative Biolabs |
100μg |
EUR 3794 |
|
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy. |
Recombinant Anti-BSA x Anti-CD3 Bispecific Antibody (Tandem scFv) |
|
BSFV-c001-50ug |
Creative Biolabs |
50μg |
EUR 2156 |
|
Description: A bispecific antibody that is expressed as an anti-BSA scFv fused with an anti-CD3 scFv, contains a His-tag at the C/N terminus for affinity purification. This BsAb can be used as a negative control to other anti-CD3 BsAbs in the research of tumor therapy. |
 Quality Control |
|
abx098966-1vial |
Abbexa |
1 vial |
EUR 300 |
|
|
) Donkey IgG (Control, non-immune, isotype control) |
|
20028-1 |
Alpha Diagnostics |
1 mg |
EUR 164 |
-control Control/blocking peptide) Rat neurofascin (Nfasc)-control Control/blocking peptide |
|
AB-23249-CP |
Alpha Diagnostics |
100ug |
EUR 164 |
) Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Fab-scFv-Fc) |
|
FABVC-030-100ug |
Creative Biolabs |
100μg |
EUR 3911 |
|
Description: A bispecific antibody that the Fab of anti-CD123 antibody variable domain is fused to the Fc-knob domain with a hinge region and the same as the scFv of anti-CD3 to the Fc-hole domain, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
Recombinant Anti-CD123 x Anti-CD3 Bispecific Antibody (Fab-scFv-Fc) |
|
FABVC-030-50ug |
Creative Biolabs |
50μg |
EUR 2390 |
|
Description: A bispecific antibody that the Fab of anti-CD123 antibody variable domain is fused to the Fc-knob domain with a hinge region and the same as the scFv of anti-CD3 to the Fc-hole domain, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of Acute myelogenous leukemia (AML); Chronic myelogenous leukemia (CML); Plasmacytoid leukemia therapy. |
 (Isotype control)) Rat IgG-Biotin conjugate (isotype control) (Isotype control) |
|
20005-B |
Alpha Diagnostics |
100 ug |
EUR 164 |
 (Isotype control)) Rat IgG-FITC conjugate (isotype control) (Isotype control) |
|
20005-F |
Alpha Diagnostics |
100 ug |
EUR 164 |
 (Isotype control)) Rat IgG-HRP conjugate (isotype control) (Isotype control) |
|
20005-HP |
Alpha Diagnostics |
100 ug |
EUR 164 |
 (Isotype control)) Rat IgG-PE conjugate (isotype control) (Isotype control) |
|
20005-PE |
Alpha Diagnostics |
25 tests |
EUR 202 |
 GFP Lentivirus Control |
|
LTV-300 |
Cell Biolabs |
1 vial |
EUR 566 |
|
Description: HIV-1 Lentivirus |
 RFP Lentivirus Control |
|
LTV-301 |
Cell Biolabs |
1 vial |
EUR 566 |
|
Description: HIV-1 Lentivirus |
 CHO Control Antigen |
|
F063 |
Cygnus Technologies |
50 ul |
EUR 219 |
|
|
|
Description: CHO Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 SF9 Control Antigen |
|
F127 |
Cygnus Technologies |
50 ul |
EUR 240 |
|
|
|
Description: SF9 Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 S.cerevisiae Control Antigen |
|
F132 |
Cygnus Technologies |
50 ul |
EUR 219 |
|
|
|
Description: S.cerevisiae Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 L.lactis Control Antigen |
|
F497 |
Cygnus Technologies |
50 ul |
EUR 257 |
|
|
|
Description: L.lactis Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 PER.C6 Control Antigen |
|
F536 |
Cygnus Technologies |
70 ul |
EUR 334 |
|
|
|
Description: PER.C6 Control Antigen by Cygnus Technologies is available in Europe via Gentaur. |
 CEL-BSA Control |
|
STA-302 |
Cell Biolabs |
100 µg |
EUR 322 |
Description: - N-epsilon-(carboxyethyl) lysine (CEL) modified BSA may be used as a positive control. 100 µg at 1 mg/mL in PBS.
- Provided at 1 mg/mL in 1X PBS
|
 MG-BSA Control |
|
STA-306 |
Cell Biolabs |
100 µg |
EUR 322 |
Description: - Methylglyoxal-BSA (MG-BSA) may be used as a positive control. 100 µg at 1 mg/mL in PBS.
- Provided at 1 mg/mL
|
 CML-BSA Control |
|
STA-314 |
Cell Biolabs |
100 µg |
EUR 322 |
Description: - CML-BSA may be used as a positive control. 100 µg.
- Provided at 1 mg/mL in 1X PBS
|
 MDA-BSA Control |
|
STA-333 |
Cell Biolabs |
100 µg |
EUR 322 |
Description: - MDA-BSA (Malondialdehyde-BSA) may be used as a positive control. 100 µg.
- Provided at 1 mg/mL in 1X PBS
|
 HNE-BSA Control |
|
STA-335 |
Cell Biolabs |
100 µg |
EUR 322 |
Description: - HNE-BSA (4-Hydroxynonenal-BSA) may be used as a positive control. 100 µg.
- Provided at 1 mg/mL in 1X PBS
|
 Goat IgG Control |
|
GT15900 |
Neuromics |
1 mg |
EUR 166 |
 Kemptide Negative Control |
|
5-01422 |
CHI Scientific |
4 x 5mg |
Ask for price |
 Rabbit Control IgG |
|
AC005 |
Abclonal |
100 ul |
EUR 133 |
 Mouse Control IgG |
|
AC011 |
Abclonal |
100 ul |
EUR 133 |
 Rat Control IgG |
|
AC034 |
Abclonal |
100 ul |
EUR 133 |
 siRNA Negative Control |
|
20-abx941273 |
Abbexa |
|
|
|
|
 Rabbit Isotype Control |
|
abx200646-100ug |
Abbexa |
100 ug |
EUR 328 |
|
|
 IgG control Antibody |
|
abx234182-100ug |
Abbexa |
100 ug |
EUR 481 |
|
|
 Compstatin control peptide |
|
B5478-1 |
ApexBio |
1 mg |
EUR 373 |
 Mouse IgG1 Control |
|
ICIGG1A-50 |
ImmunoStep |
50 µg |
EUR 323 |
Mouse IgG1 Control |
|
ICIGG1AC750-50 |
ImmunoStep |
50 µg |
EUR 713 |
Mouse IgG1 Control |
|
ICIGG1CFB-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG1 Control |
|
ICIGG1F-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
Mouse IgG1 Control |
|
ICIGG1PE-50 |
ImmunoStep |
50 µg |
EUR 323 |
Mouse IgG1 Control |
|
ICIGG1PP-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG1 Control |
|
ICIGG1PP5.5-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG1 Control |
|
ICIGG1PU-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
 Mouse IgG2a Control |
|
ICIGG2AA-50 |
ImmunoStep |
50 µg |
EUR 323 |
Mouse IgG2a Control |
|
ICIGG2AB-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
Mouse IgG2a Control |
|
ICIGG2ACFB-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG2a Control |
|
ICIGG2AF-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
Mouse IgG2a Control |
|
ICIGG2APE-50 |
ImmunoStep |
50 µg |
EUR 323 |
Mouse IgG2a Control |
|
ICIGG2APP-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG2a Control |
|
ICIGG2APP5.5-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG2a Control |
|
ICIGG2APU-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
 Mouse IgG2b Control |
|
ICIGG2BA-50 |
ImmunoStep |
50 µg |
EUR 323 |
Mouse IgG2b Control |
|
ICIGG2BCFB-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG2b Control |
|
ICIGG2BF-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
Mouse IgG2b Control |
|
ICIGG2BPE-50 |
ImmunoStep |
50 µg |
EUR 323 |
Mouse IgG2b Control |
|
ICIGG2BPP-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG2b Control |
|
ICIGG2BPP5.5-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG2b Control |
|
ICIGG2BPU-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
 Mouse IgG3 Control |
|
ICIGG3A-50 |
ImmunoStep |
100 µg |
EUR 648 |
Mouse IgG3 Control |
|
ICIGG3CFB-100 |
ImmunoStep |
100 µg |
EUR 388 |
Mouse IgG3 Control |
|
ICIGG3F-100 |
ImmunoStep |
100 µg |
EUR 323 |
Mouse IgG3 Control |
|
ICIGG3PE-50 |
ImmunoStep |
50 µg |
EUR 518 |
Mouse IgG3 Control |
|
ICIGG3PU-100 |
ImmunoStep |
100 µg |
EUR 323 |
 Mouse IgM Control |
|
ICIGMF-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
Mouse IgM Control |
|
ICIGMPU-100 |
ImmunoStep |
100 µg |
EUR 199.5 |
Rabbit Isotype Control |
|
IMN-001 |
ImmunoStep |
100 µg |
EUR 199.5 |
 TRAF6 Control Peptide |
|
H-7606.0001 |
Bachem |
1.0mg |
EUR 506 |
|
Description: Sum Formula: C139H232N34O42; CAS# [852690-80-3] net |
 Control Magnetic Beads |
|
M1302-1 |
Biovision |
|
Ask for price |
 FMK Negative Control |
|
1122-100 |
Biovision |
|
EUR 175 |
Lastly, we offer a theoretical however concrete use case for utilizing the abovementioned knowledge for higher informing choices to forestall and mitigate shortages. In doing so, we clarify the interlink between affected person wants at nation stage, demand from financial actors, intra-EU parallel commerce and manufacturer-imposed provide quotas and suggest a mechanism for collaboration between nationwide competent authorities and provide chain stakeholders for early detection and motion to forestall drugs shortages from occurring.
